Availability of Eli Lilly drugs through Hims & Hers traces back to expansion announced in April
Key Facts
Available information does not confirm a new collaboration announcement by Eli Lilly and Hims & Hers on November 6; the documented event dates to April 23, 2026, when Investing.com reported that the Hims & Hers platform had expanded access to Eli Lilly’s weight-loss drugs. According to coverage that day, providers on the platform could send prescriptions to LillyDirect pharmacy. This date defines the scope of the news that could be verified and does not establish that a new announcement was issued on the date of the current story. The expansion came amid the platform’s offering of approved GLP-1 drugs, with Hims & Hers customers gaining access to self-pay prices. The company said its licensed providers would continue to provide care, while the drugs would be dispensed through independent pharmacies.
The drugs cited in the April expansion included Zepbound vials, the KwikPen version and Foundayo, with prescriptions sent to LillyDirect and self-pay prices available to Hims & Hers customers. Under this arrangement, the platform provides a route to Lilly drugs through a prescription sent by a provider, while the pharmacy handles dispensing. Hims & Hers said its providers, who offer ongoing care to customers, were now able to prescribe drugs dispensed by independent pharmacies. It added that the change enables its providers to help patients access FDA-approved GLP-1 drugs. The company’s statement described the change as an expansion of the platform’s functionality, not as a new announcement in November.
The move dates to a broader phase of restructuring Hims & Hers’ weight-loss business in the United States. On March 9, 2026, the company announced a strategic shift in the business, alongside its collaboration with Novo Nordisk to offer injectable and pill forms of Wegovy to its customers. It then expanded access to Eli Lilly drugs in April through referrals to LillyDirect. Chief Executive Andrew Dudum said the company sees “significant growth opportunities in the U.S. as the branded GLP-1 drug portfolio expands.” He described the Novo collaboration as a model bringing together pharmaceutical companies and consumer platforms, pointing to two distinct routes for making branded treatments available through Hims & Hers.
Investing.com’s coverage linked the April expansion to changes in the market for FDA-approved GLP-1 treatments and said Hims & Hers had described its moves as a strategic shift in its U.S. weight-loss business. On February 6, 2026, the FDA had announced its intention to take steps against GLP-1 ingredients used in unapproved compounded drugs. The agency named Hims & Hers among companies marketing those products as similar alternatives to approved drugs. It said it was targeting ingredients intended for unapproved compounded drugs that were being widely marketed in this way. This regulatory context frames the company’s shift toward offering approved drugs through prescriptions and independent pharmacies.
In trading, Eli Lilly shares closed at 1364.73 on November 5, 2026, the last close before the news date given in the current version. This reading alone does not provide evidence of a market reaction to a new announcement on November 6, as no new announcement that day could be verified. The reaction reported by Investing.com concerned the April expansion: Hims & Hers shares rose 7% after the platform announced it would enable providers to prescribe Eli Lilly drugs to customers. That move was tied to the April announcement session, not the November session. Hims & Hers is scheduled to report its third-quarter 2026 results after the market closes on Monday, November 9, the company’s next financial disclosure date.